Quoin Pharmaceuticals, Ltd. QNRX
Set alert
4.34 USD +0.32 +7.96%
As of Nov 3, 9:46 AM ET
4.02 Day range 4.34
3.25 52-week range 23.50
- YTD
- -69.92%
- 1 year
- -57.99%
- Open
- 4.20
- Prev close
- 4.02
- Mkt cap
- 20.85M
- Vol
- 7.48K
- Avg vol
- 544.47K
- EPS
- -5.67
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.02
- High
- 4.34
- Forward P/E
- -0.43
- Beta
- 1.89
- Short ratio
- 0.20
- Inst. own
- 5.89%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.69104
- 200-d avg
- 0.6863
- 1y target
- 4.50
3M chart
Signals (16)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 16, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 2.64M
- Enterprise value
- -6.59M
- Trailing P/E
- 0.00
- Forward P/E
- -0.43
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.09
- EPS (TTM)
- -3.66
- Beta
- 1.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.05M
- Total cash
- 12.57M
- Total debt
- 3.22M
- Return on equity
- -100.03%
- Shares outstanding
- 5.05M
- Short % of float
- 0.48%
- 50-day average
- 0.69104
- 200-day average
- 0.6863
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 4.50 +3.7% upside
Now 4.34
- Target (low)
- 1.50
- Target (mean)
- 4.50
- Target (high)
- 10.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.43.
Financials — quick view
QNRX Revenue — quarterly 0
QNRX Net income — quarterly -5.37M
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.44 | -0.47 | -0.03 | -6.82% |
| Aug 8, 2024 | Jun 1, 2024 | -0.75 | -0.39 | +0.36 | +48.00% |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.11 | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -2.37 | -2.08 | +0.29 | +12.24% |
| Nov 8, 2023 | Sep 1, 2023 | -2.40 | -1.95 | +0.45 | +18.75% |
| Aug 2, 2023 | Jun 1, 2023 | 0.00 | -2.13 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 15, 2024 | Maxim Group | main | Buy | Buy |
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- quoinpharma.com
News
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome
- Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18
- Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome
- This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue
- Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Your note
Sign in to keep a note on QNRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER DENISE P | Chief Operating Officer | Purchase | Sep 3, 2024 | 47,092 |
| DUNN GORDON | Chief Financial Officer | Purchase | Sep 9, 2024 | 28,856 |
| MYERS MICHAEL | Chief Executive Officer | Purchase | Sep 3, 2024 | 47,252 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.77% | 38,691 | 20.20K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.63% | 31,854 | 16.63K | Sep 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 0.50% | 25,119 | 13.11K | Sep 29, 2024 |
| Virtu Financial LLC | 0.50% | 25,165 | 13.14K | Sep 29, 2024 |
| UBS Group AG | 0.45% | 22,821 | 11.91K | Sep 29, 2024 |
| Rhumbline Advisers | 0.41% | 20,786 | 10.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 95 | 49 | Apr 29, 2024 |